50
Participants
Start Date
December 31, 2011
Primary Completion Date
February 28, 2013
Study Completion Date
March 31, 2014
Pazopanib and TH-302
Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
Duke Cancer Institute, Durham
Collaborators (2)
National Comprehensive Cancer Network
NETWORK
GlaxoSmithKline
INDUSTRY
Threshold Pharmaceuticals
INDUSTRY
Herbert Hurwitz, MD
OTHER